Literature DB >> 25460503

ADAM10 and ADAM17: New players in trastuzumab tesistance.

Michael J Duffy1, John Crown2, Maeve Mullooly3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25460503      PMCID： PMC4294375          DOI： 10.18632/oncotarget.2794

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  7 in total

Review 1.  The role of ADAMs in disease pathophysiology.

Authors:  Michael J Duffy; Eadaoin McKiernan; Norma O'Donovan; Patricia M McGowan
Journal:  Clin Chim Acta       Date:  2009-05       Impact factor: 3.786

2.  High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Authors:  Jiyoung Rhee; Sae-Won Han; Yongjun Cha; Hye Seon Ham; Hwang-phill Kim; Do-Youn Oh; Seock-Ah Im; Jong-Wan Park; Jungsil Ro; Keun Seok Lee; In Hae Park; Young-Hyuck Im; Yung-Jue Bang; Tae-You Kim
Journal:  Breast Cancer Res Treat       Date:  2010-10-09       Impact factor: 4.872

3.  Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Authors:  Christoph A Ritter; Marianela Perez-Torres; Cammie Rinehart; Marta Guix; Teresa Dugger; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

4.  HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.

Authors:  Merel Gijsen; Peter King; Tim Perera; Peter J Parker; Adrian L Harris; Banafshé Larijani; Anthony Kong
Journal:  PLoS Biol       Date:  2010-12-21       Impact factor: 8.029

5.  The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

Authors:  Michael J Duffy; Maeve Mullooly; Norma O'Donovan; Sumainizah Sukor; John Crown; Aisling Pierce; Patricia M McGowan
Journal:  Clin Proteomics       Date:  2011-06-09       Impact factor: 3.988

Review 6.  HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.

Authors:  J C Singh; K Jhaveri; F J Esteva
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

7.  ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Authors:  Katharina Feldinger; Daniele Generali; Gabriela Kramer-Marek; Merel Gijsen; T B Ng; Jack Ho Wong; Carla Strina; Mariarosa Cappelletti; Daniele Andreis; Ji-Liang Li; Esther Bridges; Helen Turley; Russell Leek; Ioannis Roxanis; Jacek Capala; Gillian Murphy; Adrian L Harris; Anthony Kong
Journal:  Oncotarget       Date:  2014-08-30
  7 in total
  7 in total

Review 1.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

Review 2.  The role of ADAM17 in tumorigenesis and progression of breast cancer.

Authors:  Hongyu Shen; Liangpeng Li; Siying Zhou; Dandan Yu; Sujin Yang; Xiu Chen; Dandan Wang; Shanliang Zhong; Jianhua Zhao; Jinhai Tang
Journal:  Tumour Biol       Date:  2016-09-22

Review 3.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

Review 4.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

Review 5.  Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.

Authors:  Aura Muntasell; Mariona Cabo; Sonia Servitja; Ignasi Tusquets; María Martínez-García; Ana Rovira; Federico Rojo; Joan Albanell; Miguel López-Botet
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 6.  Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.

Authors:  Marcia L Moss; Dmitry Minond
Journal:  Mediators Inflamm       Date:  2017-11-02       Impact factor: 4.711

7.  Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.

Authors:  Astrid O Leech; Sri HariKrishna Vellanki; Emily J Rutherford; Aoife Keogh; Hanne Jahns; Lance Hudson; Norma O'Donovan; Siham Sabri; Bassam Abdulkarim; Katherine M Sheehan; Elaine W Kay; Leonie S Young; Arnold D K Hill; Yvonne E Smith; Ann M Hopkins
Journal:  Breast Cancer Res       Date:  2018-11-20       Impact factor: 6.466
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.